Generic Drugs Account for an Increasing Proportion of Total Pharmaceutical Sales across the Major Markets as a Number of Factors Drive Increased Usage.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. -- Research and Markets (http://www.researchandmarkets.com/reports/c46042) has announced the addition of "Generics will Play an Increasingly Important Role in the Pharma Industry" to their offering. A series of key patent expiries combined with the growing pressures of an aging population and an increasing need to contain rising healthcare costs worldwide are driving increased use of generics. This brief examines the factors driving this growth and its impact on the generics companies Scope of this title: What factors are driving increased generic prescriptions across the major pharmaceutical markets? How is consolidation changing the competitive landscape within the generics market? What strategies are the major generics companies using to secure their own futures? Highlights of this title: Generic drugs generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. account for an increasing proportion of total pharmaceutical sales across the major markets as a number of factors drive increased usage Reasons to order your copy: Discover the key drivers of the growth in generic prescriptions that is being seen across the major pharmaceutical markets Understand how the changing generics market is impacting the leading generics companies Topics Covered: * -A combination of patent expiries and cost containment cost containment, n the features of a dental benefits program or of the administration of the program designed to reduce or eliminate certain charges to the plan. policies will drive growth in the generics market * -A series of patent expiries on major products will present generics companies with significant opportunities * -Generic use in the US will be driven by a number of recent changes and policies, including the impact of Medicare Medicare, national health insurance program in the United States for persons aged 65 and over and the disabled. It was established in 1965 with passage of the Social Security Amendments and is now run by the Centers for Medicare and Medicaid Services. Part D * -Use of generics has traditionally been lower in some of the major pharma markets, including Japan, France and Spain Spain, Span. España (āspä`nyä), officially Kingdom of Spain, constitutional monarchy (2005 est. pop. 40,341,000), 194,884 sq mi (504,750 sq km), including the Balearic and Canary islands, SW Europe. * -Pressure on the price of generics will continue to increase in some markets, such as France and Spain * -M&A activity is becoming an essential part of the business model for generic companies * -Teva and Sandoz For the pre-1996 company, see . Sandoz is the generics subsidiary of Novartis, a multinational pharmaceutical company. The company develops, manufactures and markets off-patent medicines as well as pharmaceutical and biotechnological active ingredients. dominated the market in 2005 and recent acquisitions will enable them to continue to do so * -Several traditionally regional players are looking to expand on a global level through M&A * -Maximising profitability through lower costs of production is also driving M&A activity * -A diverse product portfolio is becoming the standard business model * -The Generics market is defined by low margins, although diversified diversified (di·verˑ·s portfolios are offering improved profitability * -The recent wave of acquisitions has also increased the diversity of generics companies portfolios * -Competition and pricing pressures are shifting the generics market to high value goods * -Few companies in the generic market focus on one type of product * -Biosimilars provide a new opportunity, but will form a very different market * -Biosimilars will drive growth for a number of generics and biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. companies * -A number of factors will make this a very different market to that of generic small molecule drugs For more information visit http://www.researchandmarkets.com/reports/c46042 Source: Datamonitor |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion